PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?


Journal

Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133

Informations de publication

Date de publication:
12 2022
Historique:
received: 23 07 2022
revised: 25 08 2022
accepted: 01 09 2022
pubmed: 5 10 2022
medline: 20 12 2022
entrez: 4 10 2022
Statut: ppublish

Résumé

Peptide receptor radionuclide therapy (PRRT) is a widely accepted treatment for progressive grade 1 and 2 (G1-2) gastroenteropancreatic neuroendocrine tumors (NET). There is increasing evidence that PRRT is effective for selected patients with well-differentiated (WD) G3 NET, which are now separated from neuroendocrine carcinoma (NEC). These preliminary data have led to prospective PRRT trials currently in progress. This article provides an update of the current role of PRRT for patients with WD-G3 NET, highlighting the importance of patient selection based on molecular imaging phenotype, as well as outlining some potential future directions in this field. Upcoming prospective trials will help define the role, sequencing, and optimization of PRRT to improve outcomes of patients with WD-G3 NET.

Identifiants

pubmed: 36195008
pii: S1471-4892(22)00120-5
doi: 10.1016/j.coph.2022.102293
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102293

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement None for Grace Kong. Although not relevant to any material in this manuscript, Professor Hicks is a shareholder of Telix Pharmaceuticals and Founder and Shareholder of PreMIT Pty Ltd.

Auteurs

Grace Kong (G)

Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

Rodney J Hicks (RJ)

The University of Melbourne Department of Medicine, St Vincent's Hospital, Melbourne, Australia. Electronic address: rod.hicks@premit.net.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH